LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts have a “Moderate Buy” consensus on LENZ Therapeutics, with five buy, two hold, and one sell rating among eight analysts. The average 12-month price target is $28.80.
• LENZ shares recently traded at $4.09, near their 12-month low of $4.01 and well below the 12-month high of $50.40. Institutional investors own 54.32% of the company, with BlackRock and other firms establishing or expanding positions.
• The company reported a quarterly loss of $1.02 per share, slightly better than estimates, while revenue of $5.49 million exceeded expectations. LENZ’s lead product, VIZZ, was approved by the FDA in July 2025 for treating adult presbyopia.

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $28.80.

LENZ has been the topic of a number of research reports. Weiss Ratings lowered LENZ Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, September 9th. Citigroup restated a "buy" rating on shares of LENZ Therapeutics in a report on Wednesday, August 12th. Piper Sandler dropped their price objective on shares of LENZ Therapeutics from $12.00 to $7.00 and set a "neutral" rating for the company in a report on Wednesday, August 12th. Zacks Research upgraded shares of LENZ Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 13th. Finally, HC Wainwright reissued a "buy" rating on shares of LENZ Therapeutics in a report on Tuesday, July 7th.

Institutional Trading of LENZ Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of LENZ Therapeutics in the 2nd quarter valued at $13,019,000. Blue Owl Capital Holdings LP bought a new stake in LENZ Therapeutics in the second quarter worth approximately $4,298,000. Primecap Management Co. CA acquired a new position in shares of LENZ Therapeutics during the 2nd quarter valued at $2,682,000. Bank of America Corp DE raised its holdings in shares of LENZ Therapeutics by 377.4% during the first quarter. Bank of America Corp DE now owns 547,534 shares of the company's stock valued at $5,010,000 after purchasing an additional 432,846 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in LENZ Therapeutics by 16.0% in the second quarter. Squarepoint Ops LLC now owns 1,747,096 shares of the company's stock worth $9,924,000 after acquiring an additional 240,597 shares in the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Price Performance

LENZ stock traded down $0.04 during trading on Friday, reaching $4.09. 85,408 shares of the company were exchanged, compared to its average volume of 913,850. The company has a market capitalization of $128.51 million, a price-to-earnings ratio of -1.00 and a beta of 0.66. The company has a 50-day moving average of $5.08 and a two-hundred day moving average of $7.36. LENZ Therapeutics has a twelve month low of $4.01 and a twelve month high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analysts' expectations of $2.38 million. LENZ Therapeutics had a negative net margin of 586.74% and a negative return on equity of 53.39%. On average, analysts forecast that LENZ Therapeutics will post -4.18 EPS for the current year.

About LENZ Therapeutics

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for people with presbyopia, an age-related condition that reduces the eye's ability to focus on near objects. The company's lead product is VIZZ (aceclidine hydrochloride ophthalmic solution), a prescription eye drop designed to improve near vision by creating a pinhole effect through pupil modulation while aiming to preserve distance vision.

In July 2025, the U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.